Please login to the form below

Not currently logged in
Email:
Password:

Wyeth makes new hires

Wyeth makes two new appointments to its Women's Health Care Business Unit

The pharmaceutical division of Wyeth has appointed Cathy Kerzner to the position of senior vice-president and general manager of the company's Women's Health Care Business Unit.

Kerzner will lead the commercial aspects of Wyeth's portfolio of the unit's products on a global basis and will report to Joseph Mahady, president of global businesses of Wyeth Pharmaceuticals.

She had spent 14 years with Wyeth in a number of commercial capacities before advancing to the position of vice-president of business strategy and then vice-president of commercial strategy for Cardinal Health. Kerzner founded EKR Therapeutics, a US-based start-up specialty pharmaceutical company.

In addition, Wyeth has promoted Dr Michael Dey to the position of president of scientific affairs for women's health. Dey will focus on efforts to advance the understanding of the science that supports both new and existing female healthcare products at the firm. He will also report to Mahady.

Dey joined Wyeth-Ayerst R&D in 1984 and headed Wyeth's generic pharmaceutical business for eight years. Since 2001, he has served as president and general manager of the Women's Health Care arm.

30th September 2008

Share

PMEA Awards 2020

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Havas Life Medicom

We’re a specialist-led, unified communications agency delivering connected healthcare communications, informed through fresh insights, smart thinking and inspired ideas. Our...

Latest intelligence

What’s in it for me? How to engage, motivate and support staff with internal training at OPEN Health
...
Environmental impact of in-person vs. virtual meetings
Although it will be tempting to resume in-person activities in the same capacity as before, we need to weigh the pros and cons of virtual vs. in-person vs. hybrid events...
US biosimilars
The US celebrates five years of biosimilars on the market – a look to the past, present and future
Why the success of biosimilars in the US has been mixed...

Infographics